相关实验视频
Updated: Sep 15, 2025

09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
1.8K
心血管学期刊发表临床试验中的数据共享声明:定量和定性分析
Yingxin Liu1, Gregory Y H Lip2,3, Jingyi Zhang1
1Center for Clinical Epidemiology and Methodology (CCEM), The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China.
Scientific data
|July 15, 2025
概括
许多心血管疾病期刊要求数据共享声明,但遵守情况尚不清楚. 这项研究分析了78个期刊,发现出版率各不相同,并探索不合规的原因,以提高临床试验中的数据共享透明度.
科学领域:
- 心脏病学 心脏病学
- 医疗信息学 医疗信息学
- 研究诚信研究诚信
背景情况:
- 心血管疾病 (CVD) 期刊通常需要为临床试验提交数据共享声明.
- 事实上,CVD期刊对这些陈述的实际出版合规性没有得到充分的证据.
研究的目的:
- 量化评估CVD临床试验中数据共享声明的发布实践.
- 质量地探讨在发布这些声明时不合规的原因.
主要方法:
- 对78个CVD期刊进行了定量分析,这些期刊在2019年1月至2022年12月期间发表了临床试验,并有数据共享声明政策.
- 采用多变量逻辑回归来确定与声明发布相关的因素.
- 一项在线定性调查分发给CVD期刊的总编辑,以收集关于非出版的见解.
主要成果:
- 该研究发现,在CVD期刊中,数据共享声明的发布率各不相同.
- 分析显示了特定期刊特征与发表这些声明的可能性之间的关联.
- 定性数据为编辑提供了关于声明出版障碍的深入观点.
结论:
- 目前在CVD期刊中发布数据共享声明的做法需要改进.
- 了解编辑的观点对于制定提高心血管临床试验数据共享和透明度的战略至关重要.
相关概念视频
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials
8.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.6K
Cardiovascular Drugs: Classification based on Therapeutic Indications
3.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
178
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
178
Coronary Artery Disease III: Clinical Manifestations
37
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
37
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
342
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
342

